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Objective: The current systematic review and meta-analysis of randomized controlled trials (RCTs) was
conducted to summarize the effect of mobile health (m-health) interventions on lipid proﬁles among
patients with metabolic syndrome and related disorders.
Methods: Cochrane Library, EMBASE, PubMed, and Web of Science databases were searched to indentify
the relevant randomized clinical trials published up April 30th, 2018. Two reviewers examined study
eligibility, extracted data, and assessed risk of bias of included clinical trials, individually. Heterogeneity
was measured using I-square (I2) statistic and Cochran's Q test. Data were pooled the standardized mean
difference (SMD) effect size by the random-effect model.
Results: 18 trials of 1681 citations were identiﬁed to be appropriate for the current meta-analysis.
Findings random-effects model indicated that m-health interventions signiﬁcantly decreased total-
(SMD 0.54; 95% CI, 1.05, 0.03) and LDL-cholesterol levels (SMD 0.66; 95% CI, 1.18, -0.15). M-health
interventions had no signiﬁcant effect on triglycerides (SMD 0.14; 95% CI, 0.56, 0.28) and HDL-
cholesterol levels (SMD 0.35; 95% CI, 0.81, 0.11).
Conclusion: Overall, the current meta-analysis demonstrated that m-health interventions resulted in an
improvement in total- and LDL-cholesterol, but did not affect triglycerides and HDL-cholesterol levels.
© 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.1. Introduction
Increased total cholesterol and triglycerides, and reduced HDL-
cholesterol levels are major risk factors for cardiovascular disease
(CVD) and stroke [1]. CVD is the leading cause of morbidity and
mortality worldwide [2]. More than 80% of deaths were attributed
to CVD and diabetes mellitus in low- and middle-income countries
[3]. Metabolic disorders have become a marker of the increasing
health inequalities in the worldwide, highlighting the urgent need
to implement more effective and cost-effective interventions [4].ier Ltd. All rights reserved.Multiple treatments and treatment approaches are documented to
decrease of main cardiovascular events. However, interventions
that modify lifestyle are among the most effective, are poorly
adhered to [5].
New advanced technologies represent a feasible solution for
decreasing the complex educational requirement. Existing data
have demonstrated the feasibility and high acceptance rate of these
technologies especially mobile health (m-health) interventions
such as smartphone, mobile phone, short message service (SMS)
and mobile application for CVD, diabetes and metabolic syndrome
(MetS) care, however their effectiveness in improving lipid proﬁle
and glycemic control, or promoting the other aspects of diabetes
and CVD management are not fully clariﬁed which might be
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design [6,7]. In a study by Rossi et al. [8], it was seen that the use of
“Diabetes Interactive Diary” (DID) in patients with type 1 diabetes
mellitus (T1DM) signiﬁcantly decreased the risk of moderate/se-
vere hypoglycemia and improved quality of life, but did not affect
HbA1c. Moreover, using SMS for 12 weeks in people with type 2
diabetes mellitus (T2DM) signiﬁcantly decreased total- and LDL-
cholesterol, but did not affect other lipid proﬁles [9]. However,
adding mobile application coaching and patient/provider web
portals to community primary care than standard diabetes man-
agement for 12 months among patients with T2DM did not affect
lipid proﬁles [10]. In addition, educational intervention using the
internet and a SMS by cellular phone for 12months in patients with
T2DM maintained glycemic control, but did not inﬂuence lipid
proﬁles [11]. Discrepancies in these ﬁndings may be due to differ-
ences in study design, characteristics of study populations, different
technologies used in mobile and duration of the intervention.
We are aware of no systematic review or meta-analyses of
randomized controlled trials (RCTs) evaluating the effect of m-
health interventions on lipid proﬁles. Thus, the current meta-
analysis was conducted to summarize the available evidence
regarding the effect of m-health interventions on lipid proﬁles
among patients with metabolic syndrome and related disorders.
2. Methods
2.1. Literature search strategy
The online databases were systematically search through
PubMed, EMBASE, Web of Science and Cochrane Library databases
until April 30th, 2018. RCTs that were investigated the effects of m-
health interventions/and or solution on lipid proﬁles identiﬁed
using the following texts word and MeSH terms: metabolic syn-
drome (MetS) and related disorders ["diabetes” OR 00T1DM” OR
00T2DM” OR “overweight” OR “obese” OR “coronary heart disease
(CHD)" OR “MetS” OR “hypercholesterolemic"]; intervention (“m-
health" OR “mobile health” OR “smartphone” OR “mobile phone”
OR “cell phone” OR” Short Message Service (SMS)" OR ""mobile
application” OR “mobile app” AND “solution” OR “intervention” OR
“health promotion” OR “health behavior")]; and outcomes ["tri-
glycerides (TG)" OR “total cholesterol (TC)" OR “LDL-cholesterol
(LDL-cholesterol)" OR “HDL-cholesterol (HDL-cholesterol)"]. Two
reviewers were conducted searches, independently. Reference lists
of the included clinical trials and review articles were scanned
manually for additional relevant studies. The search strategy of our
meta-analysis was limited to English-language publications and
there is no restriction to time of publication.
2.2. Selection criteria
RCTs were included in our meta-analysis if those met the
following inclusion criteria: 1) being a original human randomized
clinical trial (with parallel or cross-over design), 2) study partici-
pants hadmetabolic diseases, 3) clinical trials were investigated the
administration of m-health interventions and/or solutions on lipid
proﬁles, and 4) sufﬁcient information reported for mean (SD)
changes of triglycerides, total-, LDL-, HDL-cholesterol levels at
baseline and at the end of intervention in both intervention and
control groups. Clinical trial ﬁndings in abstracts without full texts,
case reports, and those did not achieve the at least required score of
quality assessment process were excluded.
2.3. Quality assessment
Two reviewers were individually assessed the methodologicalquality of included clinical trials (MA and RT) by using the Cochrane
Collaboration Risk of Bias tool. The scaling tool includes the
following criteria about each risk of bias item: selection bias
(random sequence generation and allocation concealment
description, performance bias (blinding of participants and per-
sonal process), detection bias (blinding of outcome assessment),
attrition bias (incomplete outcome data or withdrawal of patients
addressed), reporting bias (selective reporting), and other source of
bias (e.g. bias of study design, study stopped early, extreme baseline
imbalance, fraudulent trial). In case of disagreement was resolved
by the discussion or approved with third author (ZA).
2.4. Data extraction
Two authors (MA and RT) were extracted data from primary
selected clinical trials, individually.
Data extracted from each clinical trial using a standardized
electronic form of Microsoft Excel 2007 includes the following
items: The ﬁrst author's name, year of publication, sample size (in
intervention and control groups), study location, the characteristics
of study participant, m-health technology type, duration of inter-
vention, outcome measures (mean (SD) changes for triglycerides,
total-, LDL- and HDL-cholesterol at baseline and at the end of
intervention in both mhealth intervention and control groups). Any
calculation on extracted data such as converting measuring units
was performed by the ﬁrst author (MA). Any disagreement on data
extraction was resolved by discussion with the third reviewer (ZA).
2.5. Data synthesis and analysis
We were performed our meta-analysis to estimate the treat-
ment effect of m-health interventions on lipid proﬁles using stan-
dardized mean differences (SMDs) and random effects model. For
statistical analyses were used Review Manager V.5.3 software
(Cochrane Collaboration, Oxford, UK) and STATA version 12.0 (Stata
Corp., College Station, TX). Heterogeneity was measured using the
Cochran (Q) and I-squared tests (I2) for each outcome across clinical
trials. When I2 exceeded 50% or P< 0.05 were considered as het-
erogeneity across clinical trials. Subgroup analyses were conducted
based on population target (Diabetic vs. non diabetic), duration of
study (6 months vs. >6 months), total sample size (<100 vs.
100), income country [lower middle income countries (LMICs) vs.
higher middle income countries (HICs)], m-health technology type
(phone calls vs. Smartphone and/or app vs. SMS) to explore causes
of inconsistency in trial results. A sensitivity analyses was con-
ducted to evaluate the reliability of the pooled SMD by using the
leave-one-out method. Egger's regression- and Begg's tests were
used to detect the probability of publication bias. A P-value less
than 0.05 were considered as statistically signiﬁcant.
3. Results
3.1. Characteristics of included studies
Forty-four clinical trials met eligible for evaluating with more
details by full text review. Based on our inclusion and exclusion
criteria, twenty-six studies were excluded due to not an RCT
(n¼ 14), no relevant outcome reported (n¼ 5), being study proto-
col (n¼ 4), and not control group (n¼ 3). Overall, 18 clinical trials
were included into our meta-analysis. Fig. 1 shows the process of
step by step literature screening and study selection.
Sixteen clinical trials have reported the effects of m-health in-
terventions on triglycerides, seventeen on total-cholesterol, sixteen
on LDL-cholesterol, and sixteen on HDL-cholesterol levels. These
clinical trials were published between 1998 and 2017. The total
Fig. 1. Flowchart for the selection of eligible studies.
Table 1
Characteristics of included studies.
Authors (Ref) Publication
year
Sample size (control/
intervention)
Country/population
Yoon et al. [11] 2008 26/25 Korea/type 2 diabeti
Hyman et al. [20] 1998 58/65 Texas/hypercholeste
Lim et al. [13] 2016 42/43 Italy/type 2 diabetic
Waki et al. [21] 2014 27/27 Japan/type 2 diabeti
Lim et al. [22] 2011 48/49 Korea/type 2 diabeti
Goodarzi et al. [9] 2012 38/43 Iran/type 2 diabetic
Lombard et al. [23] 2010 54/64 Australia/overweigh
Zhou et al. [24] 2016 50/50 China/diabetic patien
Karhula(b) et al.
[25]
2015 60/155 Finland/type 2 diabe
Karhula(a) et al.
[25]
2015 68/168 Finland/heart diseas
Chow et al. [7] 2015 358/352 Australia/coronary H
Limaye et al. [26] 2016 132/133 India/type 2 diabete
Fukuoka et al. [19] 2015 31/30 California/overweigh
Silina et al. [27] 2017 60/63 Latvia/overweight an
Yoo et al. [12] 2009 54/57 Korea/overweight pa
diabetes
Rossi et al. [6] 2010 63/67 Italy/type 1 diabetes
Rossi et al. [8] 2013 64/63 Italy/type 1 diabetes
Quinn et al. [10] 2011 56/22 Maryland/type 2 dia
Dekkers et al. [28] 2011 49/44 Netherlands/overwe
TG, Triglycerides; TC, Total-cholesterol; LDL-C, Low-density lipoprotein-cholesterol; HDL
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dividuals in each trial), with 1520 (with range: 25e352) assigned to
m-health interventions and 1338 (with range: 26e358) to control
groups. Duration of m-health interventionswas ranged from6 to 12
months. Ten clinical trials were used Smartphone and/or app as
mhealth technology type to control lipid proﬁles, in ten trials were
SMS, and phone call used in two clinical trials as mhealth solutions.
Summary table of included trials characteristics is presented in
Table 1.
3.2. Pooled estimate of the effect of m-health interventions on lipid
proﬁles
Findings random-effects model indicated that m-health in-
terventions signiﬁcantly decreased total- (SMD 0.54; 95%
CI, 1.05, 0.03, P ¼ 0.04; I2:97.2%) and LDL-cholesterol levels
(SMD 0.66; 95% CI, 1.18, 0.15, P ¼ 0.01; I2:97.1%). M-health in-
terventionshadno signiﬁcant effect on triglycerides (SMD0.14; 95%
CI, 0.56, 0.28, P ¼ 0.51; I2:95.8%) and HDL-cholesterol levels
(SMD0.35; 95%CI,0.81, 0.11, P¼ 0.13; I2:96.4%) (Table2 and Fig. 2).
3.3. Subgroup and sensitivity analyses
Because of existence heterogeneity, we have evaluated source of
potential heterogeneity using subgroup analyses by suspected
variables including population target (diabetic vs. non-diabetic
patients), duration of study (6 months vs.>6 months), total
sample size (<100 vs. 100), income country (LMICs vs. HICs), m-
health technology type (phone calls, vs. Smartphone and/or app, vs.
SMS). Based on the ﬁndings of these analyses, the reduction of
heterogeneity was found in some of strata of suspected variables
(Table 3).
Pooled data from clinical trials using SMS interventions showed
greater reduction on serum triglycerides levels compared with theDuration M-health technology
types
Presented data
c patients 12
months
SMS TG, TC, HDL-C
rolemic 6 month Phone call TC
patients 6 month Smartphone and/or app TG, TC, LDL-C,
HDL-C
c patients 3 month Smartphone and/or app TG, LDL-C, HDL-C
c patients 6 month Smartphone and/or app TG, TC, LDL-C,
HDL-C
patients 3 month SMS TG, TC, LDL-C,
HDL-C
t women 12
month
SMS TG, TC, LDL-C,
HDL-C
ts 3 month Smartphone and/or app LDL-C
tic patients 12
month
Smartphone and/or app TG, TC, LDL-C,
HDL-C
e group 12
month
Smartphone and/or app TG, TC, LDL-C,
HDL-C
eart Disease 6 month SMS TG, TC, HDL-C
s 12
month
SMS TG, TC, LDL-C,
HDL-C
t adults 5 month Smartphone and/or app TG, TC, LDL-C,
HDL-C
d obese subjects 12
month
SMS TG, TC, LDL-C,
HDL-C
tients with both type 2 3 month Smartphone and/or app TG, TC, LDL-C,
HDL-C
6 month Smartphone and/or app TG, TC, LDL-C,
HDL-C
6 month Smartphone and/or app TG, TC, LDL-C,
HDL-C
betes 12
month
Smartphone and/or app TG, TC, LDL-C,
HDL-C
ight 6 month Phone call TC
-C, High-density lipoproteins-cholesterol.
Table 2
Estimation of the SMD of related indictors with conﬁdence interval 95% between the intervention and placebo groups.
Variable Number of study Standardized mean difference CI 95% Heterogeneity
I-squared (%) Q P-value
Triglycerides Intervention group (after vs. before) 12 0.19 0.35, 0.03 56.6 25.33 0.008
Placebo group (after vs. before) 12 0.09 0.28, 0.11 72.7 40.33 <0.001
Intervention group vs. placebo group 16 0.14 0.56, 0.28 95.8 355.06 <0.001
Total-cholesterol Intervention group (after vs. before) 14 0.22 0.47, 0.03 86.4 96.46 <0.001
Placebo group (after vs. before) 14 0.03 0.23, 0.16 77.7 58.25 <0.001
Intervention group vs. placebo group 17 0.54 1.05, 0.03 97.2 573.44 <0.001
LDL-cholesterol Intervention group (after vs. before) 12 0.16 0.55, 0.24 93.5 168.59 <0.001
Placebo group (after vs. before) 12 0.00 0.30, 0.31 89.6 105.36 <0.001
Intervention group vs. placebo group 16 0.66 1.18, 0.15 97.1 519.24 <0.001
HDL-cholesterol Intervention group (after vs. before) 12 0.13 0.10, 0.37 80.9 57.58 <0.001
Placebo group (after vs. before) 12 0.08 0.01, 0.17 2.2 11.25 0.42
Intervention group vs. placebo group 16 0.35 0.81, 0.11 96.4 417.08 <0.001
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CI: 0.92, 0.23, I2: 86.2%) (Table 3).
Total cholesterol levels signiﬁcantly decreased following m-
health interventions in pooled data from clinical trials with <100Fig. 2. The methodological quality of included studies (risk of bias).participants (0.36 mg/dL, 95% CI: 0.53, 0.19, I2: 0.0%) and with
SMS interventions (1.54 mg/dL, 95% CI: 2.87, 0.20, I2: 98.0 %)
(Table 3).
Compared with the clinical trials with 6 months, m-health
interventions with clinical trials >6 months signiﬁcantly decreased
triglycerides levels (0.17 vs. 1.51 mg/dL, 95% CI: 2.96, 0.07, I2:
98.8%). In pooled data from HICs clinical trials, LDL-cholesterol
levels signiﬁcantly decreased compared with the LMICs clinical
trials (1.85 vs. 0.39 mg/dL, 95% CI: 0.73, 0.04, I2: 92.4 %).
Similar to triglycerides and total cholesterol levels ﬁndings, serum
LDL-cholesterol levels signiﬁcantly decreased in pooled data from
clinical trials with SMS type (1.67 mg/dL, 95% CI: 3.21, 0.13, I2:
99.0 %) (Table 3).
For HDL-cholesterol levels, clinical trials were shown no sig-
niﬁcant changes between the intervention and placebo groups by
potential suspected variables (Table 3).
Sensitivity analyses were conducted to evaluate the contribu-
tion of one by one clinical trial to the overall SMD. After excluding
every clinical trial from the meta-analysis for triglycerides, LDL-
cholesterol, and HDL-cholesterol, authors found no signiﬁcant dif-
ference between the pre-sensitivity pooled SMD and post-
sensitivity pooled SMD, but there was a signiﬁcant difference be-
tween the pre- and post-sensitivity pooled SMD for total-
cholesterol after omitting Limaye et al. [27] study (SMD 0.25;
95% CI, 0.57, 0.07) (Table 4).
Fig. 3 indicates the summary of authors’ judgments regarding
the risk of bias for each included clinical trial.
3.4. Publication bias
According to the results of Egger and Begg tests, there was no
evidence of publication bias across included clinical trials for tri-
glycerides (P Egger’s test ¼ 0.52, P Begg’s test ¼ 0.32), total- (PEg ¼
0.19, PBe ¼ 0.00), LDL- (PEg ¼ 0.16, PBe ¼ 0.01), and HDL-cholesterol
(PEg ¼ 0.17, PBe ¼ 0.41).
4. Discussion
This systematic review and meta-analysis assessed the effect of
m-health interventions on lipid proﬁles in patients with MetS and
related disorders. Our ﬁndings supported that m-health in-
terventions resulted in an improvement in total- and LDL-
cholesterol, but did not affect triglycerides and HDL-cholesterol
levels.
New advanced technologies such as m-health interventions
aimed at pursuing an acceptable control of risk factors of metabolic
disturbances, including dyslipidemia and hyperglycemia. In a study
by Goodarzi et al. [9], it was seen that using SMS via mobile phone
Table 3
The effects of m-health interventions on lipid proﬁles based on subgroup analysis.
Variables Number of SMD included Subgroups Pooled OR (random effect) 95% CI I2 (%) Overall
I2 (%)
Triglycerides Population target 11 Diabetic 0.20 0.70, 0.31 94.5 95.8
5 Non-diabetic 0.02 0.90, 0.87 97.6
Duration of study 7 >6 months 0.28 1.17, 0.62 97.7
9 6 months 0.03 0.43, 0.36 91.2
Total sample size 9 100 0.12 0.77, 0.53 97.7
7 <100 0.15 0.38, 0.07 36.9
Income country 14 HICs 0.07 0.52, 0.39 95.8
2 LMICs 0.66 1.55, 0.24 92.0
M-health technology type 6 SMS 0.58 0.92, 0.23 86.2
10 Smartphone and/or app 0.12 0.56, 0.81 96.6
e Phone calls e e e
Total-cholesterol Population target 10 Diabetic 0.63 1.54, 0.29 98.0 97.2
7 Non-diabetic 0.41 0.93, 0.12 94.8
Duration of study 7 >6 months 1.07 2.46, 0.32 98.8
10 6 months 0.17 0.43, 0.09 82.5
Total sample size 10 100 0.64 1.43, 0.14 98.4
7 <100 0.36 0.53, 0.19 0.0
Income country 15 HICs 0.23 0.56, 0.11 93.0
2 LMICs 2.83 7.04, 1.38 99.4
M-health technology type 6 SMS 1.54 2.87, 0.20 98.0
9 Smartphone and/or app 0.03 0.36, 0.42 89.7
2 Phone calls 0.10 0.37, 0.16 0.0
LDL-cholesterol Population target 11 Diabetic 0.74 1.52, 0.05 97.6 97.1
5 Non-diabetic 0.51 1.18, 0.16 95.8
Duration of study 6 >6 months 1.51 2.96, 0.07 98.8
10 6 months 0.17 0.41, 0.08 78.8
Total sample size 10 100 0.76 1.50, 0.03 98.2
6 <100 0.50 0.94, 0.06 80.7
Income country 13 HICs 0.39 0.73, 0.04 92.4
3 LMICs 1.85 4.92, 1.22 99.3
M-health technology type 5 SMS 1.67 3.21, 0.13 99.0
11 Smartphone and/or app 0.20 0.52, 0.12 86.6
e Phone calls e e e
HDL-cholesterol Population target 11 Diabetic 0.50 1.22, 0.21 97.1 96.4
5 Non-diabetic 0.00 0.35, 0.36 85.7
Duration of study 7 >6 months 0.85 1.86, 0.16 98.0
9 6 months 0.06 0.15, 0.27 67.3
Total sample size 9 100 0.45 1.16, 0.26 98.0
7 <100 0.20 0.47, 0.08 58.0
Income country 14 HICs 0.11 0.32, 0.11 80.6
2 LMICs 1.94 6.26, 2.38 99.5
M-health technology type 6 SMS 0.61 1.81, 0.58 98.7
10 Smartphone and/or app 0.19 0.42, 0.04 72.4
e Phone calls e e e
Table 4
The effects of m-health interventions on lipid proﬁles based on sensitivity analysis.
Variables Pre-sensitivity analysis Upper & lower of effect
size
Post-sensitivity analysis
No. of studies
included
Pooled SMD (random
effect)
95% CI Pooled SMD (random
effect)
95% CI Excluded
studies
Triglycerides 16 0.14 0.56, 0.28 Upper 0.06 0.48, 0.36 Karhula (b)
et al.
Lower 0.12 0.57, 0.32 Rossi et al.
Total-
cholesterol
17 0.54 1.05, 0.03 Upper 0.25 0.57, 0.07 Limaye et al.
Lower 0.63 1.15, 0.11 Rossi et al.
LDL-cholesterol 16 0.66 1.18, 0.15 Upper 0.35 0.65, 0.05 Limaye et al.
Lower 0.70 1.25, 0.14 Rossi et al.
HDL-
cholesterol
16 0.35 0.81, 0.11 Upper 0.08 0.28, 0.11 Limaye et al.
Lower 0.40 0.88, 0.07 Rossi et al.
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decrease in total- and LDL-cholesterol, but did not affect other
lipids such as triglycerides and HDL-cholesterol levels. In addition,
in people with CHD, using lifestyle-focused text messaging servicecompared with usual care led to a modest improvement in LDL-
cholesterol levels and greater improvement in other cardiovascu-
lar disease risk factors, while did not inﬂuence other lipid proﬁles
[7]. Furthermore, diabetic patients receiving care through using
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Fig. 3. A-D.Meta-analysis glycemic control standardized mean differences estimates for (A) fasting glucose, (B) for triglycerides, (C) for total cholesterol, and (D) for LDL-cholesterol
in m-health interventions and controlgroups (CI¼ 95%).
M. Akbari et al. / Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13 (2019) 1949e19551954cellular phones and the internet demonstrated a signiﬁcant
improvement in HbA1c, total-, LDL-cholesterol and adiponectin
levels [12]. LDL-cholesterol accounts for most of the lipid risk in
predicting early CVD [14]. In recent years, using SMS intervention
by mobile phone has arisen as a potential means of modifying
health behaviors [15]. Previous studies have evaluated the effec-
tiveness of SMS service by mobile phone to change individual
health behaviors of smoking, weight loss, and physical activity to
improve medical management of diabetic patients [16] or adher-
ence to medication [17]. Moreover, there is very little evidence on
the effects of these services onmultiple risk factors [15]. Decreasing
some risk factors concurrently, rather than targeting single factors,
is likely to deliver greater decrease in events [18].
However, using mobile application coaching and patient/pro-
vider web portals to community primary care than standard dia-
betes management for 12 months by patients with T2DM did not
affect lipid proﬁles [10]. In addition, educational intervention
through the internet and a SMS by cellular phone for 12 months to
people with T2DM maintained glycemic control, but did not in-
ﬂuence lipid proﬁles [11]. Also, using mobile app and pedometer
intervention in people with T2DM did not affect lipid proﬁles [19].
These discrepancies in studies may be due to differences in study
design, characteristics of study populations, different technologies
used in mobile and duration of the intervention.5. Conclusions
Overall, the current meta-analysis demonstrated that m-health
interventions resulted in an improvement in total- and LDL-
cholesterol, but did not affect triglycerides and HDL-cholesterol
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